Drugs that contain Afatinib Dimaleate
1. List of Gilotrif drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE43431 | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jan, 2026
(2 years from now) | |
| US8426586 | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Oct, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE43431
(Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jul, 2026
(3 years from now) | |
| US9539258 | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
Nov, 2026
(3 years from now) | |
|
US9539258
(Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
May, 2027
(4 years from now) | |
| US8545884 | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Dec, 2029
(6 years from now) | |
|
US8426586
(Pediatric) | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Apr, 2030
(7 years from now) | |
|
US8545884
(Pediatric) | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Jun, 2030
(7 years from now) | |
| US10004743 | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jul, 2030
(7 years from now) | |
|
US10004743
(Pediatric) | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jan, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 12, 2025 |
| M | Apr 7, 2025 |
| Pediatric Exclusivity (PED) | Oct 15, 2023 |
Market Authorisation Date: 12 July, 2013
Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy
Dosage: TABLET;ORAL
How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic